Elevar Therapeutics Receives FDA Complete Response Letter for Combination of Rivoceranib and Camrelizumab as a First-line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
NDA FilingCRLrivoceranibcamrelizumabNegative
AI Analysis
Summary
Elevar Therapeutics received a complete response letter from the FDA for its new drug application of rivoceranib combined with camrelizumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma. The CRL indicates the FDA has not approved the application and requires additional information or modifications before resubmission.
Outcome Details
FDA issued a complete response letter for the combination of rivoceranib and camrelizumab as first-line treatment for unresectable or metastatic hepatocellular carcinoma
Importance:8/10
Sentiment:
-0.85
FDACRLhepatocellular carcinomacombination therapyoncologyTKIanti-PD-1
Read the original article
Published by GlobeNewswire Pharma on July 10, 2026 4:30 PM